NasdaqGM - Nasdaq Real Time Price USD

Tango Therapeutics, Inc. (TNGX)

1.1400

+0.0400

+(3.64%)

At close: May 9 at 4:00:01 PM EDT

1.1494

+0.01

+(0.82%)

After hours: May 9 at 6:44:47 PM EDT

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. “The data we are presenting at this year’s AACR meeting highlights important

GlobeNewswire last month

TNGX
+3.64%
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint

Tango Therapeutics ( NASDAQ:TNGX ) Full Year 2024 Results Key Financial Results Revenue: US$42.1m (up 15% from FY...

Simply Wall St. 2 months ago

TNGX
+3.64%
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and l

GlobeNewswire 2 months ago

TNGX
+3.64%
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Tango Therapeutics management is scheduled to participate in three upcoming investment bank conferences. The B Riley Precision Oncology & Radiopharma Conference will be held in New York, NY in late February. The Leerink Global Healthcare Conference a

GlobeNewswire 2 months ago

TNGX
+3.64%
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year

Looking at Tango Therapeutics, Inc.'s ( NASDAQ:TNGX ) insider transactions over the last year, we can see that insiders...

Simply Wall St. 2 months ago

TNGX
+3.64%
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET. A live webcast of the fireside chat ca

GlobeNewswire 3 months ago

TNGX
+3.64%
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, December 03, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducemen

Business Wire 5 months ago

TNGX
+3.64%
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, November 27, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET.

Business Wire 5 months ago

TNGX
+3.64%
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Tango Therapeutics Inc. (NASDAQ:TNGX) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, […]

Insider Monkey 5 months ago

TNGX
+3.64%
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Tango Therapeutics ( NASDAQ:TNGX ) Third Quarter 2024 Results Key Financial Results Revenue: US$11.6m (up 8.2% from 3Q...

Simply Wall St. 5 months ago

TNGX
+3.64%
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

BOSTON, November 06, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2024, and provided business highlights.

Business Wire 5 months ago

TNGX
+3.64%
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

BOSTON, November 06, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced an update on its PRMT5 program. Based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 phase 1/2 clinical trial, the Company has selected TNG462 to move forward into full development. TNG908, an MTA-cooperative brain penetrant PRMT5 inhibitor, is clini

Business Wire 5 months ago

TNGX
+3.64%
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 6 months ago

TNGX
+3.64%
Tango Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, August 28, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in September.

Business Wire 8 months ago

TNGX
+3.64%
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

While inflation has eased to 2.9% in July, interest rates remain elevated, with the Federal Reserve’s key rate currently at 5.25% to 5.50%. However, it is widely expected that the Fed will begin cutting rates as early as next month. A reduction in rates is likely to send ripples across various sectors, with the biotech industry being particularly affected. Biotech companies, which often operate with significant overhead costs, are especially sensitive to changes in interest rates. But with a rat

TipRanks 8 months ago

INZY

TNGX
+3.64%
Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Tango Therapeutics ( NASDAQ:TNGX ) Second Quarter 2024 Results Key Financial Results Revenue: US$19.9m (up 36% from 2Q...

Simply Wall St. 8 months ago

TNGX
+3.64%
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

BOSTON, August 07, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2024, and provided business highlights.

Business Wire 8 months ago

TNGX
+3.64%
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

BOSTON, June 05, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET.

Business Wire 10 months ago

TNGX
+3.64%
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.

PR Newswire 11 months ago

TNGX
+3.64%

MVIR.ST
Tango Therapeutics Announces Discontinuation of TNG348 Program

BOSTON, May 23, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program.

Business Wire 11 months ago

TNGX
+3.64%

Performance Overview

Return	TNGX	S&P 500 (^GSPC)
YTD	-63.11%	-3.77%
1-Year	-85.33%	+8.55%
3-Year	-78.61%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

One Tango Therapeutics Insider Raised Stake By 400% In Previous Year

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds

Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics to Participate in Upcoming Investor Conferences

Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics Announces Discontinuation of TNG348 Program

Performance Overview